Table 1.
General characteristics of the reviewed articles
| Author, Country | Sample size (Total Sample) | Age at Survey (Mean, SD) | Sex | Ethnicity | Cancer Type | Cancer Stage | Time Since Diagnosis in Years (Mean, SD) |
|---|---|---|---|---|---|---|---|
| Herschbach et al. [23], Germany | 174 | Total: 53.7(10.2), CBT: 53.7(9.6), SET: 53.8(10.6), Control: 53.7(10.3) | 85.7% female | German | Breast, colorectal, bladder/prostate, gynecological, etc. | No information | No information |
| van de Wal et al. [24], The Netherlands | 88 | Total: 58.9, CBT: 58.0(11.3), CAU: 59.7(10.0) | 53% female | Dutch | Breast, prostate, and colorectal cancer | No information | CBT: 2.4(1.5), CAU: 2.8(1.3) |
| Butow et al. [26], Australia | 222 | Total: 52.8(10.1), ConquerFear 53.3(10.5), Control 52.3(9.6) | 95% female | Australian | Mixed (breast, colorectal, or melanoma) | 0-3 | ConquerFear (median): 2.26, control(median):2.43 |
| Lengacher et al. [27], USA | 322 | Total: 56.6(9.7), MBSR: 57.6(9.2), Control: 56.5(10.2) | 100% female | 69.4% non-Hispanic Whites | Breast | 0-3 | No information |
| Bower et al. [37], USA | 71 | Total: 46.9 MAPS: 46.1, Control: 47.7 | 100% female | 76.1% Non-Hispanic Whites | Breast | 0-3 | MAPS: 4.0(2.4), Control: 4.1(2.3) |
| Johns et al. [38], USA | 91 |
Total: 58.7(10.7), ACT: 59.8(11.1), SE: 57.5(10.5), EUC: 58.7(10.5) |
100% female | 83.52% non-Hispanic Whites | Breast | 1-3 | No information |
| Dodds et al. [39], USA | 28 | Total: 55.3, CBCT: 54.7(12.1), Control: 55.8(9.7) | 100% female | Non-Hispanic Whites | Breast | 1-4 | CBCT: 4.8(3.2), Control: 5.8(6.0) |
| Gonzalez-Hernandez et al. [40], Spain | 56 | Total: 52.1 (7.0), CBCT: 51.6(6.9), TAU: 52.6(7.2) | 100% female | Spanish | Breast | 1-3 | CBCT: 11.32(1.44), Control: 10.46(2.90) |
| Lengacher et al. [41], USA | 82 | Total: 57.2(9.2) | 100% female | 71.9% non-Hispanic Whites | Breast | 0-3 | No information |
| Park et al. [42], Japan | 74 | Total: 53.7, MBCT: 53.2(8.4), Control: 54.2(9.3) | 100% female | Japanese | Breast | 0-3 | MBCT: 3.27(3.10), Control: 3.43(5.41) |
| Lichtenthal et al. [43], USA | 97 | Total: 54.9, AIM-FBCR: 55.8(7.4), Control: 53.9(10.3) | 100% female | AIM-FBCR: 73.0% non-Hispanic Whites, Control: 75% non-Hispanic Whites | Breast | 0-3 | No information |
| Tomei et al. [44], Canada | 24 | Total: 55.0 (10.8), CEP: 53.9(13.5), Control: 56.0(8.3) | 100% female | 95.8% non-Hispanic Whites | Breast, gynecological and ocular melanoma | 1-3 |
Range: 0-6, CEP: 1.91(1.30), Control: 1.23(1.23) |
| van Helmondt et al. [45], The Netherlands | 262 | Total: 55.8(9.9), CBT: 55.3(10.1), CAU: 56.2(9.8) | 100% female | Dutch | Breast | No information | CBT: 2.5(1.1), Control: 2.6(1.2) |
| Heinrichs et al. [46], Germany | 180 | Total: 52.5, Patient: 52.2(11.3), Partner: 52.7(11.4) | Patient group: 100% female | German | Breast or gynecological cancer | 0-3 | No information |
| Shields et al. [47], USA | 45 | Total: 44.1, CBT: 44.2(5.0), Control: 44.0(4.1) | 100% female | 97.5% non-Hispanic Whites | Breast | 1-3 | CBT: 5.6(1.7), Control: 5.5(1.6) |
| Germino et al. [48], USA | 313 | Total: 44 | 100% female | 117 African American, 196 non-Hispanic Whites | Breast | 1-4 | No information |
| Merckaert et al. [49], Belgium | 159 | Total: 50.6 (10.1) | 100% female | Belgian | Breast | 1-3 | No information |